Insider Transactions in Q1 2021 at Cardiff Oncology, Inc. (CRDF)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2021
|
Rodney S Markin Director |
BUY
Open market or private purchase
|
Indirect |
2,900
+10.83%
|
$29,000
$10.32 P/Share
|
|
Mar 23
2021
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
10,000
+0.72%
|
$100,000
$10.24 P/Share
|
|
Mar 23
2021
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
965
+6.25%
|
$9,650
$10.34 P/Share
|
|
Mar 23
2021
|
Vicki Kelemen Exec. VP and COO |
BUY
Open market or private purchase
|
Direct |
960
+13.69%
|
$9,600
$10.31 P/Share
|
|
Mar 23
2021
|
Gary S Jacob |
BUY
Open market or private purchase
|
Direct |
2,370
+5.12%
|
$23,700
$10.41 P/Share
|
|
Mar 22
2021
|
John P Brancaccio |
BUY
Open market or private purchase
|
Direct |
3,000
+19.66%
|
$30,000
$10.95 P/Share
|
|
Mar 19
2021
|
James O Armitage Director |
BUY
Open market or private purchase
|
Direct |
4,000
+21.63%
|
$40,000
$10.82 P/Share
|
|
Mar 18
2021
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
3,000
+0.33%
|
$30,000
$10.56 P/Share
|
|
Mar 04
2021
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
1,500
+0.33%
|
$13,500
$9.27 P/Share
|
|
Jan 02
2021
|
Mark Erlander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
113
-0.83%
|
-
|
|
Jan 02
2021
|
Mark Erlander Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
260
+1.87%
|
-
|
|
Jan 02
2021
|
Vicki Kelemen Exec. VP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.61%
|
-
|
|
Jan 02
2021
|
Vicki Kelemen Exec. VP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
70
+1.35%
|
-
|